The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsui, M.
Right arrow Articles by Frelinger, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsui, M.
Right arrow Articles by Frelinger, J. A.

The Journal of Immunology, Vol 154, Issue 3 1088-1096, Copyright © 1995 by American Association of Immunologists


ARTICLES

Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition

M Matsui, RJ Moots, RJ Warburton, AL Peace-Brewer, LG Tussey, DG Quinn, AJ McMichael and JA Frelinger
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill 27599.

During the course of extensive mutagenesis of HLA-A2.1, we examined influenza A matrix peptide (FMP)-specific CTL recognition of HMy2.C1R (C1R) cells expressing mutant HLA-A2.1 molecules, sensitized with synthetic peptide, FMP 58-66, (exogenous peptide), or infected with influenza A virus (endogenous peptide). Most mutants showed equivalent presentation of exogenous and endogenous peptides to FMP-specific CTL. However, five of the mutants differed in this property. Two of the five mutants, F9L and T134K, present exogenous peptide to FMP-specific CTL, but fail to present endogenous peptide to CTL. Western blot analysis using anti-matrix protein Ab indicates that the matrix protein is expressed in these mutants after infection with virus. Interestingly, transfection of these two mutants with a minigene encoding FMP 58-66 results in efficient lysis by FMP-specific CTL. Peptide-binding assays demonstrate that the two mutations dramatically decrease the binding of FMP. However, these mutants bind FMP as well as wild type in the presence of exogenously added human beta 2-m, suggesting that the lower affinity for beta 2-m leads to the inability to present endogenous peptide. The remaining three mutants, Y27N, Q32K, and S132C, fail to present exogenous peptide, but present endogenous peptide to FMP- specific CTL. Pulse-chase analyses followed by endoglycosidase-H treatment show that the rate of maturation and processing of the five mutant HLA-A2 molecules in C1R cells is identical to that of wild type. Overall, this study suggests that the assembly and subsequent recognition of endogenous peptide differs from that of exogenous peptide.


This article has been cited by other articles:


Home page
BloodHome page
A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
Blood, July 15, 2007; 110(2): 770 - 775.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Hirano, M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansen, and L. M. Nadler
Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses.
Clin. Cancer Res., May 15, 2006; 12(10): 2967 - 2975.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. A. Rosenberg, R. M. Sherry, K. E. Morton, W. J. Scharfman, J. C. Yang, S. L. Topalian, R. E. Royal, U. Kammula, N. P. Restifo, M. S. Hughes, et al.
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma
J. Immunol., November 1, 2005; 175(9): 6169 - 6176.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. S. Serody, E. J. Collins2, R. M. Tisch, J. J. Kuhns, and J. A. Frelinger
T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type of Antigen and the Mode of Delivery
J. Immunol., May 1, 2000; 164(9): 4961 - 4967.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Fan, S. S. Tykodi, and T. J. Braciale
Recognition of a Sequestered Self Peptide by Influenza Virus-Specific CD8+ Cytolytic T Lymphocytes
J. Immunol., February 15, 2000; 164(4): 1669 - 1680.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. L. M. Vissers, I. J. M. De Vries, M. W. J. Schreurs, L. P. H. Engelen, E. Oosterwijk, C. G. Figdor, and G. J. Adema
The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes
Cancer Res., November 1, 1999; 59(21): 5554 - 5559.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.